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abstract
OBJECTIVES: Unintended variation in the care of patients with Crohn
disease (CD) and ulcerative colitis (UC) may prevent achievement of
optimal outcomes. We sought to improve chronic care delivery and
outcomes for children with inflammatory bowel disease by using
network-based quality improvement methods.
METHODS: By using a modified Breakthrough Series collaborative
structure, 6 ImproveCareNow Network care centers tested changes
in chronic illness care and collected data monthly. We used an inter-
rupted time series design to evaluate the impact of these changes.
RESULTS: Data were available for 843 children with CD and 345 with UC.
Changes in care delivery were associated with an increase in the pro-
portion of visits with complete disease classification, measurement of
thiopurine methyltransferase (TPMT) before initiation of thiopurines,
and patients receiving an initial thiopurine dose appropriate to their
TPMT status. These were significant in both populations for all process
variables (P , .01) except for measurement of TPMT in CD patients
(P = .12). There were significant increases in the proportion of CD
(55%–68%) and UC (61%–72%) patients with inactive disease. There
was also a significant increase in the proportion of CD patients not
taking prednisone (86%–90%). Participating centers varied in the
success of achieving these changes.
CONCLUSIONS: Improvements in the outcomes of patients with CD and
UC were associated with improvements in the process of chronic ill-
ness care. Variation in the success of implementing changes suggests
the importance of overcoming organizational factors related to quality
improvement success. Pediatrics 2012;129:e1030–e1041
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TPMT—thiopurine methyltransferase
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As many as 1.4 million Americans suf-
fer from inflammatory bowel disease
(IBD), Crohn disease (CD), and ulcer-
ative colitis (UC).1,2 Childhood IBD is
particularly aggressive, and children
experience significant psychosocial
impact.3 Surgical intervention is fre-
quently required.4 Despite thera-
peutic advances in the treatment of
pediatric IBD, including widespread
use of immunomodulators5–7 and anti–
tumor necrosis factora agents,8 there
has been limited improvement in out-
comes over the last several deca-
des.9
There is widespread variation in the
management of IBD due to a lack of
consensus on best management prac-
tices and inadequate care delivery sys-
tems.10 This variation in delivery of care
includes diagnostic and nutritional
interventions, suboptimal dosing of
medications, prolonged use of cor-
ticosteroids, failure to use steroid-
sparing agents, inadequate attention
to metabolic bone disease, and inade-
quate screening for colorectal can-
cer.11,12
The creation of networks of care
centers has been an important ave-
nue to accelerate research in pedi-
atrics.13,14 Few centers have enough
patients to determine if changes in
care delivery are making a differ-
ence.15 Networks are increasingly
being used as a means to enable mul-
tiple clinical centers to work together
to apply quality improvement (QI)
strategies to improve care and out-
comes.14,16–20
Reducing unwanted variation and im-
proving care is difficultwithout a system
for creating new approaches to care,
testing them, and translating them into
the actual care of patients. Here, we
report the effects of QI support by the
ImproveCareNow Network (https://
improvecarenow.org/) on the process




We used an interrupted time series
design, in which measurements are re-
peated over multiple time points, to as-
sess the impact of changes aimed at
improving the system of chronic illness
care by pediatric gastroenterology cen-
ters participating in the ImproveCareNow
Network. All participating centers and the
data-coordinating center either received
Institutional Review Board approval or
were classified as exempt from review.
ImproveCareNow Network
Adetailed description andhistory of the
ImproveCareNow Network has been
previously published.20 In brief, par-
ticipating centers received training
and coaching in the Model for Improve-
ment,21 changes consistent with the
Chronic Illness Care Model,22–26 high
reliability principles,27 and team build-




This report is based on an analysis of
centers that joined the network in 2007.
Participating centers were asked to con-
tribute to the costs of creating the tech-
nical infrastructure (QI and data sharing)
for the network. We included data from
practice centers meeting the following
criteria: (1) no extensive QI experience
before formation of the network and (2)
enrollment of at least 75% of their IBD
patients.We includeddata frompatients if
they had at least 2 recorded visits, 1 of
whichwasat least90daysafterdiagnosis.
Data from patients were included until
a patient was no longer followed by the
practice, withdrew consent, and, in the
case of UC, underwent colectomy.
Interventions: QI and Chronic
Care
As described previously,20 the network
was designed between 2004 and 2006,
measures and targets identified,28 and
evidence-based changes in care delivery
selected. We used a modified Break-
through Series collaborative operational
structure.29,30 Centers received monthly
reports summarizing their performance
and that of the entire network.
We used the Chronic Illness Care
Model22–26 as the conceptual framework
to develop changes in care delivery. In-
tegrating evidence and consensus op-
inion, the network initially developed
a set of recommendations to standard-
ize diagnosis, classify disease severity,
and evaluate nutritional and growth
status. Teams developed and shared
tools and information about how to
simplify the process of implementing
these changes and documenting their
performance. As these care processes
improved, the network developed stan-
dardized recommendations for initiating
thiopurine treatment and managing
nutrition and growth. Performance
goals were expanded to include disease
remission, use of corticosteroids, and
nutritional and growth status. Addi-
tional interventions effective in improv-
ing chronic care22,23,31 were selected.
Centers developed additional tools to
support them, including: a population
tracking and management tool; a Model
IBD Care Guideline32 emphasizing re-
duced use of prednisone and improved
use of immunomodulators and biologic
agents; previsit planning templates to
ensure appropriate medication dosing,
nutrition and growth classification, and
laboratory monitoring; and flow dia-
grams to illustrate the use of protocols
and auditing. To promote development
of high reliability processes, data ele-
ments for disease classification were
reported as an all-or-nothing bundle.
Data Collection and Measures
Centers sought to enroll all of their pa-
tients with IBD and to collect data from
all visits. Dataonpatient characteristics,
disease status, and care provided were
collected during each encounter by
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using structured clinical encounter
forms.Datawereenteredintoan Internet-
based database hosted by Clinipace
Worldwide (Chapel Hill, NC).
Consistent with the definition of a sys-
tem,33 process measures of several
dimensions of the chronic care model
were selected to reflect the reliability
of important interrelated care pro-
cesses that, taken together, could be
associated with improved outcomes,
including (1) completion of a standard-
ized assessment bundle, defined as the
assessment and documentation at each
visit of all of the following: disease se-
verity, disease phenotype, extent of dis-
ease, plotting height, weight, and BMI
on a growth chart, and assessment of
nutritional and growth status; (2) mea-
surement of thiopurine methyltrans-
ferase (TPMT) before treatment with a
thiopurine; and (3) dose of thiopurine
prescribed (for patients with an in-
termediate TPMT activity, azathioprine
dose between 1.0 and 1.5 mg/kg per day
or 6-mercaptopurine dose between 0.5
and 0.75 mg/kg per day; for patients
with a normal to high TPMT activity,
azathioprine dose between 2.0 and
3.0 mg/kg per day or 6-mercaptopu-
rine dose between 1.0 and 1.5 mg/kg
per day). Process measures were sum-
marized as the proportion of visits
each month in which the process was
completed.
The primary patient outcomes were: (1)
remission,measuredas theproportionof
patients whose disease was classified as
quiescentbyphysicianglobalassessment
(PGA)20; (2) nutritional status, measured
as BMI z-score; (3) growth, defined as the
proportion of patients with a height ve-
locity z-score$ 21; and (4) steroid-free
treatment, measured as the proportion
of patients not taking prednisone after
112 days (16 weeks) past diagnosis.
Height velocity z-scores were calculated
only for boys#17 years and girls#14
years to exclude patients who no lon-
ger had significant growth potential.
Calculation of height velocity was also
limited to patients who had been diag-
nosed for at least 112 days because any
intervention would not be expected to
affect height velocity for several months.
In addition, patients were not included in
this measurement until they had at least
2 postenrollment height measurements.
Prednisone usage was only measured in
patients who had been diagnosed for at
least 112 days because the use of pred-
nisone may be appropriate early in
therapy, and the emphasis was on de-
tecting prolonged or repeated courses
of corticosteroids. The Short Pediatric
Crohn’s Disease Activity Index (sPCDAI),34
for patients with CD, and the Pediatric
Ulcerative Colitis Activity Index,35 for
patients with UC, were measured as
secondary outcome measures for the
subset of patients with sufficient data to
generate a score. For each outcome
measure, the response for an individual
patient at a visit was carried forward for
each subsequent month until a new visit
with a response occurred. Therefore,
summary measures at each month re-
flected patient status as of the last visit.
To provide more reliable and stable
baseline estimates of the outcome mea-
sures, data from a center were not in-
cluded in analyses until the center had
been in the network for at least 6 months
and had enrolled at least 10 patients. For
processmeasures, centerswere included
once they had been participating for 3
months. Patients who were no longer
receiving care at the center were inacti-
vated, and no visit-based data from the
patient were used past the date of in-
activation. Foroutcomemeasures,patient
data were carried forward for 90 days
past the date of inactivation. Data for UC
patients who had a colectomy were not
carried forward, nor were PCDAI scores34
for CD patients who underwent an os-
tomy. The PGA measure20 for CD patients
with an ostomy was carried forward.
Analyses
Statistical process control (SPC) meth-
ods were used to determine if there








Mean age in years, SE 14.9 (0.11) 13.8 (0.22) 14.6 (0.10)
Male (%) 53.7 45.5 51.4
Race/ethnicity, %
White 73.1 71.0 72.5
Black 10.1 10.1 10.1
Hispanic 1.4 4.9 2.4
Other 15.4 14.0 15.0
Number of patients enrolled by centera
Children’s Healthcare of Atlanta/Emory 62 18 80
Children’s Center
Inova Fairfax, Gastroenterology Associates
of Northern Virginia
204 101 305
Nationwide Children’s Hospital 318 104 422
Oklahoma University Medical Center 65 44 109
University of North Carolina 119 48 167
Vermont Children’s Hospital 75 30 105
Mean length of follow-up in days, SE 683.2 (10.5) 630.7 (18.0) 668.2 (9.1)
Mean number of visits per patient, SE 6.9 (0.15) 6.0 (0.25) 6.6 (0.13)
Disease activity at enrollment, %
Inactive 43.1 45.6 43.7
Mild 32.0 29.1 31.2
Moderate 12.8 13.4 13.1
Severe 1.3 1.7 1.4
Incomplete 10.8 10.2 10.6
a Centers are listed in alphabetical order and do not correspond to center numbers listed elsewhere in this manuscript.
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were changes in process andoutcome
measures across the participating
centers.36 For analyses of remission
rates and the percent of patients not
taking prednisone, centerline (mean)
and control limits (63 SD) were cal-
culated and displayed for the period
from July 2007 through March 2010.
The upper and lower control limits
reflected the inherent variation in the
data. Data values were added monthly,
and the centerline and control limits
FIGURE 1
Processmeasures for CD and UC. Top charts show the proportion of monthly visits with a complete standardized assessment bundle; middle charts show the
proportion of patientswho received a starting dose of thiopurine appropriate to their TPMT status; and bottomcharts show the proportion of patients inwhom
TPMTwasmeasured before initiation of thiopurine. Each chart shows change over time by quarter (Q) and year. Changes in care delivery were associated with
improvements in the processes of care.
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were updated with each new monthly
data point until 12 months had been
plotted.37 The centerline was then held
constant and not updated using new
monthly data points. Control charts
were then monitored for evidence of
significant change by using standard
SPC rules, including the presence of 1
point outside the upper or lower con-
trol limits. If it was predicted that a
sustainable change had taken place,
a new centerline was estimated, start-
ing with the data point that was outside
the previous limits.
To evaluate whether there was a sig-
nificant time trend in the process and
outcome measures, generalized linear
mixed-effect models were used to ac-
count for clustering of data by center,
with link functions dependent on vari-
able type (eg, logit link for binary data).
Models were run with terms for center,
time, and center-by-time interaction. If
the interaction term was significant,
indicating that the change over time
was different across centers, the time
trendwas estimatedwithin each center
and tested for statistical significance.
Similar analyses were conducted to
evaluate variation in patient charac-
teristics at enrollment over time. All
statistical analyses were performed by




Eight practice centers enrolled in
January 2007, and 2 additional centers
joined in July 2007. One center was ex-
cluded because it had extensive experi-
encewithQI andprevious improvements
in measures of care delivery. Three
additional centers were excluded; 1
dropped out of the network after 1 year,
and 2 were unable to enroll at least
75% of their patients with IBD because
they lacked the resources to partici-
pate fully, resulting in the inclusion of
6 centers.
The demographic and disease charac-
teristics at enrollment for the 1188
children (843 with CD and 345 with UC)
whocomposed thestudypopulationare
summarized in Table 1. One hundred
and twenty children with CD and 74
children with UC had been excluded
because they did not meet inclusion
criteria (.1 visit recorded and at least
1 visit at least 90 days after diagnosis).
FIGURE 2
Patients with inactive disease, as assessed by PGA, overall and for each practice site. The top charts are
annotated control charts showing monthly results for all centers combined. The dotted centerline
represents the mean proportion. The dashed upper and lower control limits reflected the inherent
variation in the data and were calculated as63 SD of the centerline proportion. The lower charts show
results for each center over the same time period. The proportion of patients with inactive disease
increased over time. A, uniform practices developed; B, key driver diagram presented, population
management report, previsit planning, protocols and auditing, nutrition and growth algorithm; C,
standardized assessment bundle; D, Model IBD Care Guideline; E, introduction to self-management
support.
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Improvements in Processes
of Care
As shown in Fig 1, by March 2010,
changes in care delivery were associ-
ated with an increase in the proportion
of visits with complete disease classifi-
cation (CD: 55%–93%; UC: 62%–89%),
measurement of TPMT before initiation
of thiopurine (CD: 60%–80%; UC: 50%–
73%), and patients receiving a starting
dose of thiopurine appropriate to their
TPMT status (CD: 48%–56%; UC: 23%–
64%). For each of the above variables,
there was a significant positive trend
seen in both populations (P, .01), with
the exception of measurement of TPMT
in CD patients (P = .12). Although the
rate of improvement for complete dis-
ease classification varied by center,
all centers demonstrated significant
improvement for CD patients. For UC
patients, performance significantly in-
creased at 3 centers and remained
stable for 3 centers.
Outcome Measures
The proportion of CD patients with in-
active disease increased over time. By
October 2008, there was evidence of
a significant improvement based on
SPC criteria of 1 point outside control
limits. On the basis of this finding and
the concurrent improvements in the
measures of the process of care, the
centerline, with the associated con-
trol limits, was adjusted from 55% for
the period July 2007 to September
2008 to 68% for the period October
2008 to March 2010. Figure 2A is a
control chart annotated to show the
association between changes under-
taken in the network and changes in
the proportion of CD patients with
inactive disease.
The proportion of UC patients with in-
active disease also increased (Fig 2B).
By June 2009, there was evidence of a
significant improvement based on SPC
criteria of 1 point outside control lim-
its. The centerline, with the associated
control limits, was adjusted from 61%
for the period July 2007 to May 2009 to
72% for the period June 2009 to March
2010. Figure 2 also shows the variation
in improvement across centers. Centers
with the lowest baseline rates showed
larger rates of improvement. As shown
in Fig 3, the changes observed in CD and
UC disease activity were primarily as-
sociated with a decrease in the per-
centage of patients with mild disease.
The proportion of CD patients not taking
prednisone also showed evidence of
significant improvement (Fig 4). The
centerline was adjusted from 86% for
the period July 2007 to October 2009
to 90% for the period November 2009
to March 2010. The proportion of UC pa-
tients not taking prednisone remained
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sPCDAI scores were analyzed as a sec-
ondary outcome. The proportion of pa-
tients in remission at the time of their
last visit increased, as measured by
sPCDAI, and demonstrated a significant
positive trend over time increasing
from 65% to 69% (P, .0001). Pediatric
Ulcerative Colitis Activity Index scores
also demonstrated a significant posi-
tive trend over time from 57% to 62%
(P = .04).
BMI z-scores did not change and re-
mained near the average value for
a patient’s gender and age for CD
patients (P = .51). For UC patients,
BMI z-scores decreased significantly
over time (0.40–0.29, P = .01) but re-
mained above 0. The proportion of
patients with normal height velocity
showed no change over time for ei-
ther disease group.
Supporting Analyses
We examined whether the changes
we observed could be attributed to
other causes. To assess the impact of
incomplete data in the registry, we se-
lected 20 patients at random from each
center. Overall, 87% of visits for these
patients were entered into the registry.
To determine if patients with active
disease were more likely to be enrolled
duringtheearlypartof thecollaborative,
thereby underestimating the propor-
tion of patients in remission in cen-
ters’ populations, we calculated the
remission rate of patients at enrollment
by 3-month periods and found it to be
stable over time (Fig 5). Similarly, we
also examined other patient character-
istics by 3-month intervals to determine
if the population being enrolled was
stable. There was no change in gender
proportions or BMI at the time of en-
rollment (P . .10), except for a minor
increase in BMI among UC patients (P =
.03). As anticipated, the time from di-
agnosis to enrollment decreased over
the course of the collaborative (P ,
.0001 for both CD and UC patients) be-
cause centers initially had predom-
inantly previously diagnosed patients
available for enrollment and later had
predominantly newly diagnosed pa-
tients available for enrollment. Finally,
to determine if disease activity improved
as a function of time from diagnosis, we
plotted mean duration of enrollment as
a function of time in the collaborative.
We found a very small association, in-
dicating that time from diagnosis is un-
likely to be a significant confounder.
DISCUSSION
After the creation of a collaborative
improvement network, standardiza-
tion of care, and the application of
evidenced-based changes to improve
chronic illness care, we observed im-
provements in specific care processes
and an increase in the proportion of
CD and UC patients in remission, as well
as an increase in the percentage of CD
patients not taking corticosteroids.
This project extends the findings of
other investigators that redesigning
FIGURE 3
Disease severity for CD and UC (monthly change in disease severity over time). Changes in disease
activity were primarily associated with a decrease in the percentage of patients with mild disease.
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specific elements of chronic care de-
livery leads to improvements in the
quality and outcomes of care. For ex-
ample, in 32 of 39 studies in a systematic
review of diabetes care programs, in-
terventions based on components of
the Chronic Care Model improved at
least 1 process or outcomemeasure for
diabetic patients,23 although there was
often a delay in seeing improvements in
clinical outcomes.38 Other studies and
reviews suggest that implementing
more changes results in more improve-
ment.39–42 Most of this work has taken
place in adult primary care practices.
Here, we demonstrated its relevance to
pediatric subspecialty care.
There is mounting evidence that the
use of collaborative improvement net-
works can improve patients’outcomes.
To date, much of the evidence comes
from hospital-based networks.16–19 Pri-
mary care networks have demonstrated
modest improvements in outcomes for
patients with chronic illness.43 Our re-
sults provide an estimate of the mag-
nitude of improvements in outcomes
that may take place when there is par-
ticular emphasis on more consistent
and reliable application of existing
therapies.18,19,44
Our study has several potential limi-
tations. First, the PGA of disease activ-
ity is a relatively subjective measure,
which could result in misclassification
error. It is unlikely that physicians
systematically underestimated illness
severity because accurate disease as-
sessment was essential for efficient pop-
ulation management processes. Thus,
any misclassification was likely stable
over time. Second, we cannot determine
if changes in some process measures
simply reflected improved documenta-
tion. However, accurate documentation is
essential to improve the chronic illness
care processes. For example, without ac-
curate information about drug doses,
previsit planning and population man-
agement are difficult to accomplish. Third,
improvements in outcome occurring
over time could have taken place in-
dependent of changes in care delivery as
part of the network. No external com-
parator group was available to help with
this determination. However, not all cen-
ters showed improvement, and the im-
provement we observed took place over
a relatively short period of time during
which no new therapies were introduced
into routine clinical practice. Finally, the
processes we measured may not be
directly responsible for the observed
improvement in remission. Rather, as
hypothesized by the Chronic Illness
Care Model,22–26 these measures are
tracers that indicate improvements in
the overall systems of care delivery.
As anticipated, improvements did not oc-
cur equally across measures or across
FIGURE 4
Percent of CD andUC patients not taking prednisone (annotated control charts showingmonthly results
forall centers combined). The dotted centerline represents themean proportion. The dashed upperand
lower control limits reflected the inherent variation in the data and were calculated as 63 SD of the
centerline proportion. The proportion of CD patients, but not UC patients, increased over time. A,
uniform practices developed; B, key driver diagram presented, population management report, pre-
visit planning, protocols and auditing, nutrition and growth algorithm; C, standardized assessment
bundle; D, Model IBD Care Guideline; E, introduction to self-management support.
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centers. Three centers were unable to
participate fully in the network, dem-
onstrating that a significant investment
of time and resources is required simply
to participate. Of those centers that were
included, some began with high perfor-
mance on specific measures and main-
tained that level of care, while others
started at lower levels of process reli-
ability and either improved or remained
relatively stable. Such variation in the
success of the center-based QI efforts
FIGURE 5
CharacteristicsofCDandUCpatientsat the timeofenrollment (change inremissionrates, gender,BMI, and time fromdiagnosis forpatientsenrolled in thestudy
over time). Therewasnochange ingenderproportionsat the timeof enrollment. Therewasaminor increase inBMIamongUCpatients. The time fromdiagnosis
to enrollment decreased over the course of the collaborative.
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likely reflects differences in the degree
of implementation of the interventions
or the impact of other contextual fac-
tors, such as focused leadership and
availability of resources to support QI
(eg, training, staff devoted to the effort,
and allocated physician time).33,45–59
As the network has matured, we have
increased the availability of focused
coaching to centers which are not dem-
onstrating improved performance to ad-
dress issues of training, implementation,
and leadership. A better understanding
of these factorswill allowmore effective
application of QI methods and, thereby,
potentially even greater improvements
in outcomes.
Similarly, improvements did not occur
equally across measures. While im-
provements were noted in many pro-
cess and outcome measures, there
was not consistent improvement in
anthropometrics. This lack of improve-
ment could be attributed to several po-
tential explanations, including (1) a lag
period between improvement in re-
mission rates and subsequently growth
and nutrition parameters, (2) the fact
that improvement occurred most pro-
minently in those withmild disease and,
therefore, with fewer growth issues at
baseline, and (3) baseline z-scores were
near or above 0, leaving little room for
improvement.
CONCLUSIONS
These results suggest that col-
laborative QI methods focused on
improving chronic illness care can lead
to improved process and outcome
measures in childrenwith IBD, and likely
in other chronic diseases as well. These
improvements were likely the result of
changes in the care delivery systems
rather than a single specific interven-
tion. We believe that improvement will be
more consistent across centers as the
package of care delivery system changes
is more reliably and comprehensively
implemented. Further study is needed to
determine which combination of inter-
ventions is most important to improve
the outcomes of these patients. Our data
suggest that there are opportunities to
substantially improve outcomes in pe-
diatric IBD by using therapeutic inter-
ventions that are already available.
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